Suven Life Sciences Ltd. - Research Center
530239 SUVEN Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Sales | 14.41 | 285.67 | 625.26 | 544.48 | 499.52 |
| Operating profit | -35.26 | 48.70 | 232.92 | 165.34 | 123.25 |
| Interest | 0.54 | 1.90 | 4.61 | 5.67 | 5.42 |
| Gross profit | -21.77 | 74.04 | 251.58 | 180.77 | 137.19 |
| EPS (Rs) | -1.08 | 3.08 | 12.45 | 9.70 | 7.46 |
Annual
results in details
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Other income | 14.04 | 27.25 | 23.27 | 21.09 | 19.35 |
| Stock adjustment | - | -9.29 | -21.20 | -2.96 | -12.05 |
| Raw material | - | 79.62 | 174.90 | 154.81 | 178.45 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 14.60 | 33.85 | 58.74 | 50.64 | 41.64 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | 25.94 | 59.37 | 58.47 | 64.94 | 62.95 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 9.14 | 73.43 | 121.44 | 111.70 | 105.28 |
| Provisions made | - | - | - | - | - |
| Depreciation | 4.17 | 10.79 | 21.31 | 21.41 | 16.72 |
| Taxation | -12.18 | 24.06 | 71.84 | 35.88 | 25.50 |
| Net profit / loss | -13.75 | 39.19 | 158.43 | 123.47 | 94.97 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 12.73 | 12.73 | 12.73 | 12.73 | 12.73 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | 509.12 |
| Agg.of non promotoholding (%) | - | - | - | - | 40.00 |
| OPM (%) | -244.63 | 17.05 | 37.25 | 30.37 | 24.67 |
| GPM (%) | -76.51 | 23.66 | 38.79 | 31.96 | 26.44 |
| NPM (%) | -48.34 | 12.53 | 24.43 | 21.83 | 18.30 |
Mutual Fund Selector
Find the fund that is right for you
© 2020 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis